Biomea Fusion, Inc. BMEA
0.63 USD +0.01 (+1.46%)
Nov 4, 2026, 11:38 AM EST
0.6215 Day range 0.6745
0.552 52-week range 2.24
- YTD
- -48.96%
- 1 year
- -49.77%
Benzinga news
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers MaxCyte (NASDAQ:MXCT) shares rose 34.5% to $1.3 during Wednesday's regular session. The company's market cap stands at $102.6 million. Liquidia (NASDAQ:LQDA) stock moved upwards by 26.29% to…
benzinga.com Citizens Reiterates Market Outperform on Biomea Fusion, Maintains $7 Price Target Citizens analyst Jonathan Wolleben reiterates Biomea Fusion (NASDAQ:BMEA) with a Market Outperform and maintains $7 price target.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Liquidia (NASDAQ:LQDA) shares moved upwards by 41.0% to $37.8 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.4 billion. Greenland Mines…
benzinga.com State Street, Fastenal And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. futures were mixed. State Street fell 6.4% after missing sales estimates, while Biomea Fusion, Skydance and other stocks slid premarket.- benzinga.com HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $4 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Biomea Fusion (NASDAQ:BMEA) with a Buy and maintains $4 price target.
benzinga.com Why Enovix Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket Enovix jumps 6.8% after securing a 100,000-unit battery order from a multinational drone maker, with deliveries planned for H1 2027.
benzinga.com What’s Going On With Biomea Fusion (BMEA) Stock After Hours? Biomea Fusion reports Phase 1 BMF-650 results, with weight reduction and safety data from its oral GLP-1 drug trial.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares rose 20.5% to $3.65 during Tuesday's after-market session. The market value of their outstanding shares is at $2.6 million. Circle8 Group…
benzinga.com Biomea Fusion BMF-650 Phase 1 Weight Loss Results Remain Preliminary, With Longer-Term Trials And Toxicology Studies Still Outstanding Safety and TolerabilityAcross the five active-dose MAD cohorts (n=40), all reported treatment-emergent adverse events (TEAEs) were mild or moderate. There were no severe or serious TEAEs,…
benzinga.com Biomea Fusion Reports Phase 1 Results For Oral GLP-1 Candidate BMF-650, Showing Consistent Weight Reduction And Encouraging Tolerability Mean weight reduction ranged from 1.5% to 3.2% at Day 29 across Cohorts 1-4, compared with 0.1% for pooled placebo.No severe or serious TEAEs, no TEAE-related dose modifications, and no TEAE-related…
benzinga.com Biomea Fusion Stock Climbs 7% After-Hours: What's Going On? Biomea Fusion shares rise after-hours before Phase I results for oral GLP-1 candidate BMF-650.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Biomea Fusion (NASDAQ:BMEA) stock increased by 11.0% to $1.51 during Monday's after-market session. The market value of their outstanding shares is at $102.9 million. iTonic Holdings…
benzinga.com Biomea Fusion To Report Results From Phase I GLP-131 Clinical Study Evaluating BMF-650, Investigational Next-Gen Oral Small-Molecule GLP-1 Receptor Agonist, On October 13 Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ:BMEA), a clinical-stage biopharmaceutical company, today announced that it will report results from its Phase I GLP-131 clinical study…- benzinga.com Brookline Capital Initiates Coverage On Biomea Fusion with Buy Rating, Announces Price Target of $10 Brookline Capital analyst Kumaraguru Raja initiates coverage on Biomea Fusion (NASDAQ:BMEA) with a Buy rating and announces Price Target of $10.
benzinga.com Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data Biomea Fusion stock falls after ending a public securities offering and revising clinical data timelines for its obesity trial.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Artelo Biosciences (NASDAQ:ARTL) shares rose 216.1% to $13.12 during Wednesday's regular session. The market value of their outstanding shares is at $2.2 million. Vistagen Therapeutics…
benzinga.com Biomea Fusion Terminates Proposed Public Offering Of Securities Due To Market Conditions Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that it has terminated its proposed public offering of securities,…
benzinga.com Why Worthington Enterprises Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket Worthington Enterprises surged 15.9% premarket after beating Q1 EPS and sales estimates; Wheeler REIT led gainers, while Jaguar Health and Biomea fell.
benzinga.com Biomea Fusion Shares Fall 19% After Hours: Here’s Why Biomea Fusion shares fall nearly 19% after hours, highlighting volatility in BMEA after Tuesday's session.
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Jaguar Health (NASDAQ:JAGX) shares moved upwards by 32.2% to $45.56 during Tuesday's after-market session. The company's market cap stands at $1.1 million. Bullfrog AI Hldgs (NASDAQ:BFRG)…
benzinga.com Biomea Fusion Stock Surges on Phase II Diabetes Trial Enrollment Completion Shares of Biomea Fusion are trading sharply higher on Monday following an operational milestone for its lead metabolic drug program.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Innovative Eyewear (NASDAQ:LUCY) stock rose 63.6% to $1.12 during Monday's regular session. The market value of their outstanding shares is at $5.8 million. Picard Medical (AMEX:PMI) shares…
- benzinga.com Biomea Fusion Q2 EPS $(0.12) Beats $(0.22) Estimate Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.22) by 45.45 percent. This is a 76.47 percent increase over losses of…
- benzinga.com Reported Friday, Biomea Fusion Presents ADA Data Showing Icovamenib Delivers 1.8% Placebo-Adjusted HbA1c Reduction In T2D Patients On Background GLP-1 Therapy Translational data presented at ADA demonstrate icovamenib's potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including…
benzinga.com Biomea Fusion Partners With The University Of Leicester For Ongoing Platform Research Study Titled 'Investigating And Optimizing Physical Function With Weight Loss: A Multi-Arm Open Label Adaptive Platform Trial' Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health and Metabolic OutcomesLate-Breaking…
benzinga.com Biomea Fusion Q1 EPS $(0.17) Beats $(0.24) Estimate Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.24) by 29.17 percent. This is a 78.75 percent increase over losses of…
benzinga.com This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Citations for AMAT, BMEA, ACRS, KALU, SION.- benzinga.com Citizens Initiates Coverage On Biomea Fusion with Market Outperform Rating, Announces Price Target of $9 Citizens analyst Jonathan Wolleben initiates coverage on Biomea Fusion (NASDAQ:BMEA) with a Market Outperform rating and announces Price Target of $9.
benzinga.com Biomea Fusion Reveals 52-Week Results From Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment; In Patients Diagnosed Within 0-3 Years, Treatment With Icovamenib 200 Mg Once Daily For 12 Weeks Resulted In A 52% Increase In Mean C-peptide Area Under The Curve At Week 12 A 52% increase from baseline in mean C-peptide AUC at Week 12 in patients diagnosed within 0–3 years (n=5) receiving icovamenib 200 mg, with a clear dose response observed vs 100 mg (n=6)Persistence…- benzinga.com Biomea Fusion Starts New Trials to Test Diabetes Drug in Patients Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced that the first patient has been dosed in its…
- benzinga.com Citigroup Maintains Buy on Biomea Fusion, Raises Price Target to $7 Citigroup analyst Yigal Nochomovitz maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and raises the price target from $6 to $7.
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib Biomea Fusion (NASDAQ: BMEA) shares rose Friday after the company reported positive Phase II data for icovamenib in type 2 diabetes, highlighting durable efficacy and a favorable safety profile.
benzinga.com D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $12 Price Target D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and maintains $12 price target.- benzinga.com Biomea Fusion Expects To Enroll First Participant In COVALENT-211 Phase IIb Trial In Q1 2026, Provides Business Updates For This Year Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or "the Company") (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today outlined its execution priorities for 2026. The Company enters…
- benzinga.com Citigroup Maintains Buy on Biomea Fusion, Lowers Price Target to $6 Citigroup analyst Yigal Nochomovitz maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and lowers the price target from $7 to $6.
- benzinga.com D. Boral Capital Maintains Buy on Biomea Fusion, Lowers Price Target to $12 D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and lowers the price target from $16 to $12.
- benzinga.com Biomea Fusion Presents Preclinical Data For BMF-650 Oral Small Molecule GLP-1 At ObesityWeek In Atlanta Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or the "Company") (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the presentation of two late breaking posters…
benzinga.com Biomea Fusion Q3 EPS $(0.27) Misses $(0.26) Estimate Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.26) by 2.27 percent. This is a 70.33 percent increase over losses of…- benzinga.com D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $16 Price Target D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and maintains $16 price target.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Nasdaq Tumbles 200 Points; Trilogy Metals Shares Spike Higher 
benzinga.com Biomea Fusion Stock Plummets Following Public Offering, Diabetes Study Biomea Fusion reported favorable safety for icovamenib in a 52-week diabetes study, alongside a $25 million public offering.
benzinga.com Dow Jumps Over 100 Points; McCormick Earnings Top Views - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Biomea Fusion Announces Pricing Of Its Underwritten Public Offering Including 11,195,121 Shares Of Common Stock And 1M Pre-Funded Warrants. Each Warrant Has Exercise Price Of $2.50 And Offering Price Per Common Share And Warrant Is $2.05 Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced the pricing of its previously announced underwritten public offering consisting of (i)…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Biomea Fusion Announces Proposed Public Offering Of Securities; No Size Or Amount Disclosed Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and…
- benzinga.com Biomea Fusion Announces 52-Week Phase II Data For Icovamenib In Type 2 Diabetes; Study Shows Sustained HbA1c Reduction And Favorable Safety Profile Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient population taking one or more antihyperglycemic…
- benzinga.com D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $16 Price Target D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and maintains $16 price target.